Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Orhan Aktas

Showing results (1-10 of 267) with videos related to

Pageof 27
Sort By:
Journal of Neurology, Neurosurgery, and Psychiatry|November 12, 2014
Collateral benefit: the comeback of MOG antibodies as a biomarker in neurological practiceOrhan Aktas
Multiple Sclerosis (Houndmills, Basingstoke, England)|August 11, 2017
Shifting borders, crossing boundaries: The case of combined central and peripheral demyelinationOrhan Aktas
Journal of Neurology, Neurosurgery, and Psychiatry|March 25, 2014
Natalizumab in clinical practice: managing the risks, enjoying the benefitsOrhan Aktas
Der Nervenarzt|March 17, 2021
[From neuromyelitis optica to neuromyelitis optica spectrum disorder: from clinical syndrome to diagnistic classification]Orhan Aktas, Tania Kümpfel
Current Pharmaceutical Design|February 7, 2003
Regulation of self-reactive T cells by human immunoglobulins--implications for multiple sclerosis therapyOrhan Aktas, Frauke Zipp
Trends in Neurosciences|August 2, 2006
The brain as a target of inflammation: common pathways link inflammatory and neurodegenerative diseasesFrauke Zipp, Orhan Aktas
Annals of Neurology|March 30, 2011
Beyond axonal transection: hippocampal damage in multiple sclerosisOrhan Aktas, Hans-Peter Hartung
Annals of Neurology|October 23, 2009
Bleak prospects for primary progressive multiple sclerosis therapy: downs and downs, but a glimmer of hopeHans-Peter Hartung, Orhan Aktas
Journal of Neurology|September 22, 2009
Neuromyelitis and more: the unfolding spectrum of aquaporin 4-related neurological diseasesOrhan Aktas, Hans-Peter Hartung
The Lancet. Neurology|April 20, 2010
Oral therapies for multiple sclerosis: are we there yet?Hans-Peter Hartung, Orhan Aktas
Pageof 27

Showing results (1-10 of 267) with videos related to

Sort By:
Pageof 27
Journal of Neurology, Neurosurgery, and Psychiatry|November 12, 2014
Collateral benefit: the comeback of MOG antibodies as a biomarker in neurological practiceOrhan Aktas
Multiple Sclerosis (Houndmills, Basingstoke, England)|August 11, 2017
Shifting borders, crossing boundaries: The case of combined central and peripheral demyelinationOrhan Aktas
Journal of Neurology, Neurosurgery, and Psychiatry|March 25, 2014
Natalizumab in clinical practice: managing the risks, enjoying the benefitsOrhan Aktas
Der Nervenarzt|March 17, 2021
[From neuromyelitis optica to neuromyelitis optica spectrum disorder: from clinical syndrome to diagnistic classification]Orhan Aktas, Tania Kümpfel
Current Pharmaceutical Design|February 7, 2003
Regulation of self-reactive T cells by human immunoglobulins--implications for multiple sclerosis therapyOrhan Aktas, Frauke Zipp
Trends in Neurosciences|August 2, 2006
The brain as a target of inflammation: common pathways link inflammatory and neurodegenerative diseasesFrauke Zipp, Orhan Aktas
Annals of Neurology|March 30, 2011
Beyond axonal transection: hippocampal damage in multiple sclerosisOrhan Aktas, Hans-Peter Hartung
Annals of Neurology|October 23, 2009
Bleak prospects for primary progressive multiple sclerosis therapy: downs and downs, but a glimmer of hopeHans-Peter Hartung, Orhan Aktas
Journal of Neurology|September 22, 2009
Neuromyelitis and more: the unfolding spectrum of aquaporin 4-related neurological diseasesOrhan Aktas, Hans-Peter Hartung
The Lancet. Neurology|April 20, 2010
Oral therapies for multiple sclerosis: are we there yet?Hans-Peter Hartung, Orhan Aktas
Pageof 27